logo
logo

Xcellbio Announces $27.5 Million Series B Financing

Jan 19, 2022•over 3 years ago

Amount Raised

$27.5 Million

Round Type

series b

San Francisco

Description

Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, today announced $27.5 million in Series B financing led by Casdin Capital. Also participating in this financing are new investors Dynamk Capital, Formic Ventures, and Labcorp, as well as existing investors HBM Genomics and Viking Global Investors. In connection with the financing, Shaun Rodriguez, PhD, Director of Life Science Research at Casdin Capital, will join the Xcellbio board of directors.

Company Information

Company

Xcellbio

Location

San Francisco, California, United States

About

Xcellbio is a venture-backed company driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company’s commercial instruments and AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cell therapy manufacturing platform. Based in San Francisco, Xcellbio can also be found online at www.xcellbio.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech